Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 37

1.

Neutrophil Extracellular Traps Confine Pseudomonas aeruginosa Ocular Biofilms and Restrict Brain Invasion.

Thanabalasuriar A, Scott BNV, Peiseler M, Willson ME, Zeng Z, Warrener P, Keller AE, Surewaard BGJ, Dozier EA, Korhonen JT, Cheng LI, Gadjeva M, Stover CK, DiGiandomenico A, Kubes P.

Cell Host Microbe. 2019 Apr 10;25(4):526-536.e4. doi: 10.1016/j.chom.2019.02.007. Epub 2019 Mar 28.

PMID:
30930127
2.

Alanine Scanning Mutagenesis of the MEDI4893 (Suvratoxumab) Epitope Reduces Alpha Toxin Lytic Activity In Vitro and Staphylococcus aureus Fitness in Infection Models.

Tkaczyk C, Semenova E, Shi YY, Rosenthal K, Oganesyan V, Warrener P, Stover CK, Sellman BR.

Antimicrob Agents Chemother. 2018 Oct 24;62(11). pii: e01033-18. doi: 10.1128/AAC.01033-18. Print 2018 Nov.

3.

The Neutrophilic Response to Pseudomonas Damages the Airway Barrier, Promoting Infection by Klebsiella pneumoniae.

Jones-Nelson O, Hilliard JJ, DiGiandomenico A, Warrener P, Alfaro A, Cheng L, Stover CK, Cohen TS, Sellman BR.

Am J Respir Cell Mol Biol. 2018 Dec;59(6):745-756. doi: 10.1165/rcmb.2018-0107OC.

PMID:
30109945
4.

Pseudomonas aeruginosa PcrV and Psl, the Molecular Targets of Bispecific Antibody MEDI3902, Are Conserved Among Diverse Global Clinical Isolates.

Tabor DE, Oganesyan V, Keller AE, Yu L, McLaughlin RE, Song E, Warrener P, Rosenthal K, Esser M, Qi Y, Ruzin A, Stover CK, DiGiandomenico A.

J Infect Dis. 2018 Nov 5;218(12):1983-1994. doi: 10.1093/infdis/jiy438.

PMID:
30016475
5.

Immune stealth-driven O2 serotype prevalence and potential for therapeutic antibodies against multidrug resistant Klebsiella pneumoniae.

Pennini ME, De Marco A, Pelletier M, Bonnell J, Cvitkovic R, Beltramello M, Cameroni E, Bianchi S, Zatta F, Zhao W, Xiao X, Camara MM, DiGiandomenico A, Semenova E, Lanzavecchia A, Warrener P, Suzich J, Wang Q, Corti D, Stover CK.

Nat Commun. 2017 Dec 8;8(1):1991. doi: 10.1038/s41467-017-02223-7.

6.

A neutralizing antibody that blocks delivery of the enzymatic cargo of Clostridium difficile toxin TcdB into host cells.

Kroh HK, Chandrasekaran R, Zhang Z, Rosenthal K, Woods R, Jin X, Nyborg AC, Rainey GJ, Warrener P, Melnyk RA, Spiller BW, Lacy DB.

J Biol Chem. 2018 Jan 19;293(3):941-952. doi: 10.1074/jbc.M117.813428. Epub 2017 Nov 27.

7.

Structure and characterization of a high affinity C5a monoclonal antibody that blocks binding to C5aR1 and C5aR2 receptors.

Colley CS, Popovic B, Sridharan S, Debreczeni JE, Hargeaves D, Fung M, An LL, Edwards B, Arnold J, England E, Eghobamien L, Sivars U, Flavell L, Renshaw J, Wickson K, Warrener P, Zha J, Bonnell J, Woods R, Wilkinson T, Dobson C, Vaughan TJ.

MAbs. 2018 Jan;10(1):104-117. doi: 10.1080/19420862.2017.1384892. Epub 2017 Oct 24.

8.

Use of a neutralizing antibody helps identify structural features critical for binding of Clostridium difficile toxin TcdA to the host cell surface.

Kroh HK, Chandrasekaran R, Rosenthal K, Woods R, Jin X, Ohi MD, Nyborg AC, Rainey GJ, Warrener P, Spiller BW, Lacy DB.

J Biol Chem. 2017 Sep 1;292(35):14401-14412. doi: 10.1074/jbc.M117.781112. Epub 2017 Jul 13.

9.

Multimechanistic Monoclonal Antibodies (MAbs) Targeting Staphylococcus aureus Alpha-Toxin and Clumping Factor A: Activity and Efficacy Comparisons of a MAb Combination and an Engineered Bispecific Antibody Approach.

Tkaczyk C, Kasturirangan S, Minola A, Jones-Nelson O, Gunter V, Shi YY, Rosenthal K, Aleti V, Semenova E, Warrener P, Tabor D, Stover CK, Corti D, Rainey G, Sellman BR.

Antimicrob Agents Chemother. 2017 Jul 25;61(8). pii: e00629-17. doi: 10.1128/AAC.00629-17. Print 2017 Aug.

10.

Anti-LPS antibodies protect against Klebsiella pneumoniae by empowering neutrophil-mediated clearance without neutralizing TLR4.

Cohen TS, Pelletier M, Cheng L, Pennini ME, Bonnell J, Cvitkovic R, Chang CS, Xiao X, Cameroni E, Corti D, Semenova E, Warrener P, Sellman BR, Suzich J, Wang Q, Stover CK.

JCI Insight. 2017 May 4;2(9). pii: 92774. doi: 10.1172/jci.insight.92774. eCollection 2017 May 4.

11.

Bispecific antibody targets multiple Pseudomonas aeruginosa evasion mechanisms in the lung vasculature.

Thanabalasuriar A, Surewaard BG, Willson ME, Neupane AS, Stover CK, Warrener P, Wilson G, Keller AE, Sellman BR, DiGiandomenico A, Kubes P.

J Clin Invest. 2017 Jun 1;127(6):2249-2261. doi: 10.1172/JCI89652. Epub 2017 May 2.

12.

Complement C5a induces PD-L1 expression and acts in synergy with LPS through Erk1/2 and JNK signaling pathways.

An LL, Gorman JV, Stephens G, Swerdlow B, Warrener P, Bonnell J, Mustelin T, Fung M, Kolbeck R.

Sci Rep. 2016 Sep 14;6:33346. doi: 10.1038/srep33346.

13.

Targeting Alpha Toxin and ClfA with a Multimechanistic Monoclonal-Antibody-Based Approach for Prophylaxis of Serious Staphylococcus aureus Disease.

Tkaczyk C, Hamilton MM, Sadowska A, Shi Y, Chang CS, Chowdhury P, Buonapane R, Xiao X, Warrener P, Mediavilla J, Kreiswirth B, Suzich J, Stover CK, Sellman BR.

MBio. 2016 Jun 28;7(3). pii: e00528-16. doi: 10.1128/mBio.00528-16.

14.

Pseudomonas aeruginosa Bacteremic Patients Exhibit Nonprotective Antibody Titers Against Therapeutic Antibody Targets PcrV and Psl Exopolysaccharide.

Thaden JT, Keller AE, Shire NJ, Camara MM, Otterson L, Huband M, Guenther CM, Zhao W, Warrener P, Stover CK, Fowler VG Jr, DiGiandomenico A.

J Infect Dis. 2016 Feb 15;213(4):640-8. doi: 10.1093/infdis/jiv436. Epub 2015 Sep 2.

15.

Differential expression and roles of Staphylococcus aureus virulence determinants during colonization and disease.

Jenkins A, Diep BA, Mai TT, Vo NH, Warrener P, Suzich J, Stover CK, Sellman BR.

MBio. 2015 Feb 17;6(1):e02272-14. doi: 10.1128/mBio.02272-14.

16.

A multifunctional bispecific antibody protects against Pseudomonas aeruginosa.

DiGiandomenico A, Keller AE, Gao C, Rainey GJ, Warrener P, Camara MM, Bonnell J, Fleming R, Bezabeh B, Dimasi N, Sellman BR, Hilliard J, Guenther CM, Datta V, Zhao W, Gao C, Yu XQ, Suzich JA, Stover CK.

Sci Transl Med. 2014 Nov 12;6(262):262ra155. doi: 10.1126/scitranslmed.3009655.

17.

A novel anti-PcrV antibody providing enhanced protection against Pseudomonas aeruginosa in multiple animal infection models.

Warrener P, Varkey R, Bonnell JC, DiGiandomenico A, Camara M, Cook K, Peng L, Zha J, Chowdury P, Sellman B, Stover CK.

Antimicrob Agents Chemother. 2014 Aug;58(8):4384-91. doi: 10.1128/AAC.02643-14. Epub 2014 May 19.

18.

Fatty aldehydes in cyanobacteria are a metabolically flexible precursor for a diversity of biofuel products.

Kaiser BK, Carleton M, Hickman JW, Miller C, Lawson D, Budde M, Warrener P, Paredes A, Mullapudi S, Navarro P, Cross F, Roberts JM.

PLoS One. 2013;8(3):e58307. doi: 10.1371/journal.pone.0058307. Epub 2013 Mar 11.

19.

Identification of broadly protective human antibodies to Pseudomonas aeruginosa exopolysaccharide Psl by phenotypic screening.

DiGiandomenico A, Warrener P, Hamilton M, Guillard S, Ravn P, Minter R, Camara MM, Venkatraman V, Macgill RS, Lin J, Wang Q, Keller AE, Bonnell JC, Tomich M, Jermutus L, McCarthy MP, Melnick DA, Suzich JA, Stover CK.

J Exp Med. 2012 Jul 2;209(7):1273-87. doi: 10.1084/jem.20120033. Epub 2012 Jun 25.

20.

Synthetic lethality of PARP inhibition in BRCA-network disrupted tumor cells is associated with interferon pathway activation and enhanced by interferon-╬│.

Warrener P, Kim S, Williams SM, Biery M, Gordon M, Toniatti C, Cleary MA, Linsley PS, Carleton M.

Apoptosis. 2012 Jul;17(7):691-701. doi: 10.1007/s10495-012-0707-4.

PMID:
22392482
21.

Identification of SULF2 as a novel transcriptional target of p53 by use of integrated genomic analyses.

Chau BN, Diaz RL, Saunders MA, Cheng C, Chang AN, Warrener P, Bradshaw J, Linsley PS, Cleary MA.

Cancer Res. 2009 Feb 15;69(4):1368-74. doi: 10.1158/0008-5472.CAN-08-2742. Epub 2009 Feb 3.

22.

Small interfering RNA screens reveal enhanced cisplatin cytotoxicity in tumor cells having both BRCA network and TP53 disruptions.

Bartz SR, Zhang Z, Burchard J, Imakura M, Martin M, Palmieri A, Needham R, Guo J, Gordon M, Chung N, Warrener P, Jackson AL, Carleton M, Oatley M, Locco L, Santini F, Smith T, Kunapuli P, Ferrer M, Strulovici B, Friend SH, Linsley PS.

Mol Cell Biol. 2006 Dec;26(24):9377-86. Epub 2006 Sep 25.

23.

Molecular validation of LpxC as an antibacterial drug target in Pseudomonas aeruginosa.

Mdluli KE, Witte PR, Kline T, Barb AW, Erwin AL, Mansfield BE, McClerren AL, Pirrung MC, Tumey LN, Warrener P, Raetz CR, Stover CK.

Antimicrob Agents Chemother. 2006 Jun;50(6):2178-84.

24.

RNA interference-mediated silencing of mitotic kinesin KIF14 disrupts cell cycle progression and induces cytokinesis failure.

Carleton M, Mao M, Biery M, Warrener P, Kim S, Buser C, Marshall CG, Fernandes C, Annis J, Linsley PS.

Mol Cell Biol. 2006 May;26(10):3853-63.

25.

Mutations in the cueA gene encoding a copper homeostasis P-type ATPase reduce the pathogenicity of Pseudomonas aeruginosa in mice.

Schwan WR, Warrener P, Keunz E, Stover CK, Folger KR.

Int J Med Microbiol. 2005 Aug;295(4):237-42.

PMID:
16128398
26.

Evolutionary relationships among virulence-associated histidine kinases.

Brinkman FS, Macfarlane EL, Warrener P, Hancock RE.

Infect Immun. 2001 Aug;69(8):5207-11.

27.

Complete genome sequence of Pseudomonas aeruginosa PAO1, an opportunistic pathogen.

Stover CK, Pham XQ, Erwin AL, Mizoguchi SD, Warrener P, Hickey MJ, Brinkman FS, Hufnagle WO, Kowalik DJ, Lagrou M, Garber RL, Goltry L, Tolentino E, Westbrock-Wadman S, Yuan Y, Brody LL, Coulter SN, Folger KR, Kas A, Larbig K, Lim R, Smith K, Spencer D, Wong GK, Wu Z, Paulsen IT, Reizer J, Saier MH, Hancock RE, Lory S, Olson MV.

Nature. 2000 Aug 31;406(6799):959-64.

PMID:
10984043
28.

Antimicrobial effects of novel siderophores linked to beta-lactam antibiotics.

Kline T, Fromhold M, McKennon TE, Cai S, Treiberg J, Ihle N, Sherman D, Schwan W, Hickey MJ, Warrener P, Witte PR, Brody LL, Goltry L, Barker LM, Anderson SU, Tanaka SK, Shawar RM, Nguyen LY, Langhorne M, Bigelow A, Embuscado L, Naeemi E.

Bioorg Med Chem. 2000 Jan;8(1):73-93.

PMID:
10968267
29.

A small-molecule nitroimidazopyran drug candidate for the treatment of tuberculosis.

Stover CK, Warrener P, VanDevanter DR, Sherman DR, Arain TM, Langhorne MH, Anderson SW, Towell JA, Yuan Y, McMurray DN, Kreiswirth BN, Barry CE, Baker WR.

Nature. 2000 Jun 22;405(6789):962-6.

PMID:
10879539
30.

Characterization of a Pseudomonas aeruginosa efflux pump contributing to aminoglycoside impermeability.

Westbrock-Wadman S, Sherman DR, Hickey MJ, Coulter SN, Zhu YQ, Warrener P, Nguyen LY, Shawar RM, Folger KR, Stover CK.

Antimicrob Agents Chemother. 1999 Dec;43(12):2975-83.

31.

Detection and analysis of diverse herpesviral species by consensus primer PCR.

VanDevanter DR, Warrener P, Bennett L, Schultz ER, Coulter S, Garber RL, Rose TM.

J Clin Microbiol. 1996 Jul;34(7):1666-71.

32.

Pestivirus NS3 (p80) protein possesses RNA helicase activity.

Warrener P, Collett MS.

J Virol. 1995 Mar;69(3):1720-6.

33.

Hepatitis C virus NS3 protein polynucleotide-stimulated nucleoside triphosphatase and comparison with the related pestivirus and flavivirus enzymes.

Suzich JA, Tamura JK, Palmer-Hill F, Warrener P, Grakoui A, Rice CM, Feinstone SM, Collett MS.

J Virol. 1993 Oct;67(10):6152-8.

34.
35.
36.

Unique region of the minor capsid protein of human parvovirus B19 is exposed on the virion surface.

Rosenfeld SJ, Yoshimoto K, Kajigaya S, Anderson S, Young NS, Field A, Warrener P, Bansal G, Collett MS.

J Clin Invest. 1992 Jun;89(6):2023-9. Erratum in: J Clin Invest 1992 Dec;90(6):2609.

37.

Phosphorylation and proteolytic degradation of nucleolin from 3T3-F442A cells.

Warrener P, Petryshyn R.

Biochem Biophys Res Commun. 1991 Oct 31;180(2):716-23.

PMID:
1953744

Supplemental Content

Loading ...
Support Center